Sue Vincent, a patient diagnosed with advanced ovarian cancer in 2007, has experienced a remarkable 14-year survival thanks to olaparib, a PARP inhibitor developed by The Institute of Cancer Research. Initially given a prognosis of two to three years, Vincent's participation in an olaparib clinical trial has not only extended her life but also allowed her to witness significant family milestones. This case underscores the potential of targeted therapies in managing BRCA2-mutated cancers and highlights the importance of ongoing research in improving patient outcomes.
Initial Diagnosis and Treatment
In September 2007, Sue Vincent received a diagnosis of ovarian cancer after experiencing symptoms initially dismissed as irritable bowel syndrome. Following her diagnosis, genetic testing revealed that she carried a BRCA2 mutation, a factor that increased her susceptibility to developing cancer. Vincent underwent surgery followed by six rounds of chemotherapy, which she found challenging due to side effects such as hair loss and pain.
Recurrence and Olaparib Trial
In February 2010, routine blood tests indicated a rise in her CA125 level, a cancer marker, signaling a recurrence. By July 2010, scans confirmed that the cancer had returned in three places, rendering it inoperable. Faced with a grim prognosis, Vincent enrolled in a clinical trial for olaparib. Despite initial reservations about halting her natural remedies, she decided to pursue the trial, hoping to extend her life for her husband and daughters.
Sustained Response and Improved Quality of Life
Vincent quickly demonstrated a positive response to olaparib. Over the years, the drug has kept her cancer at bay, far exceeding her initial prognosis. Since starting olaparib, Vincent has witnessed her daughters' milestones, including marriages and the birth of five grandchildren. She emphasizes the profound impact of olaparib on her quality of life, enabling her to travel, enjoy time with family, and lead an active life.
The Importance of Cancer Research
Vincent underscores the critical role of The Institute of Cancer Research in developing life-saving treatments like olaparib. She advocates for continued support of cancer research, emphasizing its potential to improve outcomes for future generations. Her story serves as a testament to the transformative power of targeted therapies and the importance of clinical trials in advancing cancer care. She also mentioned that one of her daughters tested positive for the BRCA2 mutation and has been diagnosed with cancer, highlighting the importance of new drugs being available.
